EQT Ventures

What they fund

• High-Growth Technology — Companies leveraging AI, automation, and data analytics to transform traditional industries, such as IFS and Sana [1].
• Healthcare Innovation — Biotech and medtech firms with scalable solutions, like Amolyt Pharma, which received significant support through multiple funding rounds [1].
• Sustainable Infrastructure — Companies driving the green transition and decarbonization, such as NFI, which secured sustainability-linked financing through EQT's network [1].
• Global Scalability — Businesses with the potential to expand across Europe and the United States, leveraging EQT's global footprint and operational expertise.

Investment thesis

EQT Ventures identifies and backs "Generation-Defining Companies" with the potential to reshape their industries, leveraging a global footprint to support high-growth, ambitious founders. Guided by the EQT Group's philosophy of unlocking long-term growth and compounding capital through cycles, the firm focuses on continuous improvement and building better alternatives [1]. The firm targets founders who align with a long-term value creation mindset, aiming to shape the next decade through impactful investment.

Value add

EQT Ventures provides operational support, leveraging its global network and expertise to help portfolio companies scale. The firm actively builds leadership teams and supports strategic decisions, as seen with Amolyt Pharma and IFS [1].

Fit verdict: EQT Ventures is a strong fit for ambitious founders seeking long-term capital and operational support to build global market leaders.

Founder diligence script:

• How does EQT Ventures leverage its global network to accelerate our international expansion?
• What specific operational support does EQT provide to help us transition from a startup to a global leader?
• How does EQT's long-term investment philosophy align with our growth trajectory and exit timeline?
• What examples can you share of EQT helping portfolio companies navigate significant pivots or scaling challenges?

Portfolio focus

• Agentic AI & Enterprise Software — IFS, where EQT helped transition static scheduling tools into agentic AI, quintupling annual revenues to €1.5bn and increasing operating profit 12x [1].
• AI-Native Learning — Sana, an AI-native knowledge platform founded by Joel Hellermark, which Workday acquired for $1.1bn after EQT invested in early 2021 [1].
• Healthcare & Biotech — Amolyt Pharma, which EQT backed through a record-breaking €67m Series A and later supported through IPO preparation before its acquisition by AstraZeneca for up to $1.05bn [1].
• Infrastructure & Cloud — EdgeConneX, where EQT tripled built capacity to a global platform of 80+ data centers serving hyperscalers across cloud and AI [1].

Notable investments & exits

• Amolyt Pharma — Acquired by AstraZeneca for up to $1.05bn after EQT backed its record-breaking €67m Series A and supported IPO preparation [1].
• Sana — Acquired by Workday for $1.1bn after EQT invested in early 2021 and supported its growth as an AI-native learning platform [1].
• IFS — While not an exit, IFS's quintupled annual revenues to €1.5bn and 12x increase in operating profit demonstrate significant value creation [1].
• EdgeConneX — Tripled built capacity to a global platform of 80+ data centers, serving hyperscalers across cloud and AI [1].

Strategic implications

EQT Ventures' strength lies in its ability to identify and back "Generation-Defining Companies" with a global footprint and operational expertise. Its long-term investment philosophy and active board participation create significant value for portfolio companies. The main risk is the potential for over-involvement, which could stifle founder autonomy. A signal that would change the read is a shift towards shorter-term exits or a reduction in operational support.

Where they could go further

EQT Ventures could enhance its strategy by focusing more on early-stage investments, particularly in emerging technologies like quantum computing and synthetic biology. The firm could also improve its support for portfolio companies in navigating regulatory challenges, especially in healthcare and fintech. Additionally, expanding its network of co-investors in Asia could provide new growth opportunities for portfolio companies.